FDA restricts use of heart failure drug to 30 days

05/2/2013 | CardiovascularBusiness.com

The FDA ordered doctors to restrict the use of Otsuka Pharmaceuticals' Samsca, or tolvaptan, to 30 days or less because of potential liver damage that could result in organ transplantation or death. The treatment is indicated for clinically significant euvolemic and hypervolemic hyponatremia tied to conditions including heart failure. The agency also discourages the drug's use in patients with underlying liver disease.

View Full Article in:

CardiovascularBusiness.com

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager, Business Conduct
Gilead
Foster City, CA
Product Patent Attorney
Gilead
Foster City, CA
Employment Counsel
Gilead
Foster City, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Global Counsel - Advertising and Promotions
Mylan Inc.
Washington, DC